With chance to take on Bristol Myers' $13B heart drug, Cytokinetics preps for pivotal studies with $450M debt raise
As Cytokinetics traded near its one-year high earlier this week, execs decided to take on a load of debt. But investors aren’t liking what they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
